在轻度认知障碍中神经心理诊断工具:系统性审查和元分析
Nuria Jerez-Garrido1, Ana M Jiménez-García1, David Sánchez-Borda1
1BRABE Group, Department of Psychology, Faculty of Life and Natural Sciences, University of Nebrija, C/del Hostal, 28248 Madrid, Spain.
Aging and disease
|November 10, 2025
概括
本综述确定了用于预测阿尔茨海默病 (AD) 在轻度认知障碍 (MCI) 中进展的关键神经心理测试. 标准化认知评估对于早期诊断和有效治疗患有AD风险的MCI患者至关重要.
科学领域:
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
- 心理学 心理学 心理学
背景情况:
- 轻度认知障碍 (MCI) 影响着大量人群,其进展向阿尔茨海默病 (AD) 变化.
- 现有的认知测试显示了AD转换的不同预测值,需要对其有效性的审查.
- 准确的诊断工具对于MCI患者的及时干预至关重要.
研究的目的:
- 系统地审查和元分析最常用的神经心理测试,以预测从MCI到AD的进展.
- 为了确定MCI和健康对照个体之间的认知测试差异.
- 在MCI转换为AD的背景下评估这些测试的预测价值.
主要方法:
- 在主要的科学数据库 (PubMed,Scopus,ScienceDirect,Cochrane) 中进行了全面的系统搜索.
- 对103项选定的研究进行了随机效应元分析,但排除了缺乏对照组或不足可比数据的研究.
- 分析了认知测试表现和预测值,以确定显著的差异和趋势.
主要成果:
- 分析显示,MCI患者在全球认知,语言和情绪健康方面存在显著的认知障碍.
- 一些研究表明,MCI患者的海马缩和粉样β/tau沉积进展到AD.
- 在一些包含的研究中,也注意到了体力和认知训练的好处的证据.
结论:
- 标准化认知评估对于识别高风险转化为AD的MCI患者至关重要.
- 需要进一步的研究来完善诊断工具,并了解影响MCI进展的因素.
- 局限性包括缺少的患者数据,如MCI亚型和疾病持续时间,这可能会影响研究结果.
更多相关视频
04:33Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
1.2K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
33.7K
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
527
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
527
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782
